info@lsi-medical.com   (800) 846-1279 | fax: 855-385-7969

Author Archives: Markesha Christopher

You Can Find LSI at Any of The Upcoming 7 Conferences in March

You Can Find LSI at Any of The Upcoming 7 Conferences in March

LSI is more than just a medical device company. We are committed advocates for the cardiac and pulmonary industries. As such, LSI recognizes that state affiliate conferences are a great opportunity to network with other professionals while learning the latest in medical procedures, patient care, and regulatory guidelines. You can find LSI at any of the 7 upcoming conferences across the country in March. Read more »

Day On The Hill

Day On The Hill

Cardiac and Pulmonary Rehabilitation Professionals will have the opportunity to meet with their state legislators at AACVPR’s Day on the Hill in Washington, DC March 4 – 5, 2019. This annual event provides a platform for healthcare professionals to lobby and advocate for the industry. Previous visits to Capitol Hill focused on Bill HR.1155/S.1361 which would allow non-physician practitioners to fulfill the Medicare requirement of “direct supervision” in cardiac and pulmonary rehab programs. This bill was pass in 2018 as part of the ACCESS Act and will go into effect January 1, 2024. Read more »

Pulmonary Rehabilitation Billing Options

Pulmonary Rehabilitation Billing Options

Since 2006, AACVPR, the American Thoracic Society, the American College of Chest Physicians, and the National Association for Medical Direction of Respiratory Care have lobbied CMS to generate a national coverage determination (NCD) for pulmonary rehabilitation services to include patients with respiratory ailments other than COPD. Read More

New Whitepaper: Exercise Guidelines for Patients with PAD

New Whitepaper: Exercise Guidelines for Patients with PAD

Medically supervised exercise therapy (SET) is widely-recognized as an appropriate intervention to alleviate claudication symptoms in patients with peripheral arterial disease (PAD). It is important that intervention for this patient population also include secondary prevention of cardiac risk factors, including hypertension, hyperlipidemia, and diabetes, among others. Read more